-
1 Comment
Guizhou Bailing Group Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 11.5% below its 200 day moving average.
From a valuation standpoint, the stock is 61.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.7.
Guizhou Bailing Group Pharmaceutical Co., Ltd's total revenue sank by 0.5% to $735M since the same quarter in the previous year.
Its net income has increased by 599.0% to $52M since the same quarter in the previous year.
Finally, its free cash flow fell by 101.9% to $-11M since the same quarter in the previous year.
Based on the above factors, Guizhou Bailing Group Pharmaceutical Co., Ltd gets an overall score of 2/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| CurrencyCode | CNY |
| ISIN | CNE100000PY3 |
| Exchange | SHE |
| Market Cap | 6B |
|---|---|
| PE Ratio | None |
| Target Price | 22 |
| Beta | 0.47 |
| Dividend Yield | None |
Guizhou Bailing Group Pharmaceutical Co., Ltd. research, develops, produces, and sells medicines in China. The company provides medicines in the form of tablets, capsules, granules, syrups, powders, pills, tinctures, sprays, lotions, and cream for cardiovascular and cerebrovascular diseases, cough, cold, pediatric, and gynecologic diseases. Guizhou Bailing Group Pharmaceutical Co., Ltd. was founded in 1999 and is headquartered in Anshun, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002424.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
